Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

ABSTRACT: Background: Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multi-centre trial (NCT04568031). Methods: Adults (n=256, age ≥18 years) seronegative for...

Full description

Bibliographic Details
Main Authors: Michiko Asano, Hiroshi Okada, Yohji Itoh, Hajime Hirata, Kensuke Ishikawa, Erika Yoshida, Akiko Matsui, Elizabeth J. Kelly, Kathryn Shoemaker, Urban Olsson, Johan Vekemans
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
ChAdOx1 nCoV-19
AZD1222
Japan
Elderly adult
Humoral response
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221008183

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221008183

Similar Items